Salivary Gland Neoplasms - 20 Studies Found Recruiting : Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors : Salivary Gland Tumors Head and Neck Cancer : 2016-09-30 : Drug: Docetaxel Docetaxel only Recruiting : Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors : Salivary Gland Tumors Head and Neck Cancer : 2016-05-12 : Drug: Cisplatin Cisplatin 80mg Completed : A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors : Malignant Salivary Gland Tumors : 2011-12-07 : Drug: Cisplatin: 40 mg/m2 weekly during radiation Recruiting : Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers : Salivary Glands Tumors : 2016-08-11 : Drug: Abiraterone acetate Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of Completed : Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor : Head and Neck Cancer : 2004-03-08 : Drug: carboplatin Drug: cisplatin Recruiting : Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery : Head and Neck Cancer : 2010-10-12 : Drug: cisplatin Given IV Recruiting : A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes : Salivary Gland Cancer Metastatic Advanced Drug: Selinexor Other Name: KP Recruiting : Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample : Breast Cancer Stomach Neoplasms Sali : 2007-12-04 Withdrawn : Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies : Adenoma, Pleomorphic Mixed Salivary Gland Tumor : 2009-09-23 : Radiation: Radiation Radiation Recruiting : Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 : Salivary Gland Cancers : 2016-05-06 : Drug: Axitinib Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hour Next >>>